M
Mucosis
Mucosal vaccines to prevent infectious diseases
About Mucosis
Mucosis is a biotechnology company specializing in the development of mucosal vaccines designed to enhance immune responses against infectious diseases. Operating in the global healthcare market, Mucosis targets pharmaceutical companies, healthcare providers, and research institutions as its primary clients. The company's core product is its proprietary vaccine platform, which leverages the body's mucosal surfaces to trigger a stronger and more effective immune response. This platform is particularly advantageous for combating respiratory and gastrointestinal infections. Mucosis generates revenue through licensing agreements, partnerships, and direct sales of its vaccine technology. By focusing on innovative vaccine delivery methods, Mucosis aims to address unmet medical needs and improve public health outcomes.
Source: Dealroom company dataAt a glance
- Founded
- 2006
- Headquarters
- Groningen, Netherlands
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
MedSciences Capital
BioGeneration Ventures
Utrecht Holdings
Wellcome Trust
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Mucosis on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Mucosis on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.